The current antibody therapeutics market targeting respiratory and gastrointestinal viruses is mostly restricted due to the limitations of IgG molecules and administration by intra-venous injection. 

Icosagen is developing sIgA platform that enables to reformat existing therapeutic antibodies against respiratory and gastrointestinal viruses into an IgA isotype administrated by nebulization.